ArticleJournal of clinical immunology2010
Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.
Article in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
185 citing papers in PubMed, 388 citations in OpenAlex.
- Faecal Microbiota Transplantation Engraftment After Budesonide or Placebo in Patients With Active Ulcerative Colitis Using Pre-selected Donors: A Randomized Pilot Study.Journal of Crohn's & colitis · 2024Trial
- Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression.PloS one · 2012Trial
- Upadacitinib Outcomes After Tofacitinib Failure in Patients With Moderate to Severe Ulcerative Colitis.ACG case reports journal · 2026Article
- Characteristics of T-Cells Expressing IL-37 and Its Receptors in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Article
- Chronic obstructive pulmonary disease (COPD) and autoimmune diseases: unravelling complex interactions.Annals of medicine · 2025Review
- Effects of CCL20/CCR6 Modulators in a T Cell Adoptive Transfer Model of Colitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3Allergy · 2025Article
- Syphacia obvelata antigens alter the FOXP3/RORɣt expression balance in isolated peripheral blood mononuclear cells of IBD patients.Scientific reports · 2025Article
- CD39 as a metabolic rheostat of immunoregulation.Cellular & molecular immunology · 2025Article
- Toll-like Receptor 9 Mediates Epstein-Barr Virus-Aggravated Inflammation in a Mouse Model of Inflammatory Bowel Disease.Biomedicines · 2025Article
- The immunobiology and therapeutic potential of regulatory T cells in autoimmune diseases and allergic diseases.Frontiers in immunology · 2025Review
- Regulatory T Cell Dysfunction in Autoimmune Diseases.International journal of molecular sciences · 2024Review
- Unraveling the mechanism of malancao in treating ulcerative colitis: A multi-omics approach.World journal of clinical cases · 2024Article
- Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres.Nature biomedical engineering · 2024Article
- Cirsimaritin Alleviates Dextran Sodium Sulfate-Induced Acute Colitis in Experimental Animals: A Therapeutic Approach for Inflammatory Bowel Disease.Preventive nutrition and food science · 2024Article
- Gut Microbiota and Inflammation Modulation in a Rat Model for Ulcerative Colitis after the Intraperitoneal Administration of Apigenin, Luteolin, and Xanthohumol.International journal of molecular sciences · 2024Article
- Efficacy and Mechanism of the Action of Live and Heat-KilledACS omega · 2024Article
- Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease.Molecules (Basel, Switzerland) · 2024Review
- Probiotics to Prevent Celiac Disease and Inflammatory Bowel Diseases.Advances in experimental medicine and biology · 2024Review
125 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is thought to result from an aberrant immune response. Inflammation in IBD may be caused by the loss of homeostasis between CD4+ CD25high Foxp3+ regulatory cells (Treg) and proinflammatory Th17 cells. The aim of this study was to investigate Treg and Th17 cells in the peripheral blood and intestinal mucosa of IBD patients and to assess the mucosal cytokine environment.
methodsTreg and Th17 cells were measured in peripheral blood of 63 IBD patients and 28 controls by flow cytometry. Forkhead box p3 (Foxp3), interleukin (IL)-17a, IL-1beta, IL-6, IL-21, IL-23, and transforming growth factor (TGF)-beta mRNA were analyzed using real-time reverse transcription polymerase chain reaction in intestinal biopsies of 24 IBD and 18 control subjects.
resultsA decrease in Treg and increase in Th17 cells was observed in the peripheral blood of IBD patients. When measured in the same patient and expressed as a ratio, a significant decrease in Treg/Th17 ratio was observed in IBD. Elevated expression of Foxp3, IL-17a, IL-1beta, and IL-6 was observed in the mucosa of IBD patients, while TGF-beta was only elevated in ulcerative colitis.
conclusionIBD is associated with a reduced ratio of Treg to Th17 cells in peripheral blood and is characterized by a proinflammatory cytokine microenvironment, which supports the continued generation of Th17 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.